These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
166 related items for PubMed ID: 10963284
1. Clarithromycin in the management of community-acquired pneumonia. McCarty JM. Clin Ther; 2000 Mar; 22(3):281-94; discussion 265. PubMed ID: 10963284 [Abstract] [Full Text] [Related]
3. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones. Carratalá J, Martín-Herrero JE, Mykietiuk A, García-Rey C. Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924 [Abstract] [Full Text] [Related]
4. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. Feldman C. J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171 [Abstract] [Full Text] [Related]
5. Clinical implications of macrolide resistance in community-acquired respiratory tract infections. Hoban DJ, Zhanel GG. Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414 [Abstract] [Full Text] [Related]
8. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia? Sánchez F, Mensa J, Martínez JA, García E, Marco F, González J, Marcos MA, Soriano A, Torres A. Clin Infect Dis; 2003 May 15; 36(10):1239-45. PubMed ID: 12746768 [Abstract] [Full Text] [Related]
9. Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? Amsden GW. J Antimicrob Chemother; 2005 Jan 15; 55(1):10-21. PubMed ID: 15590715 [Abstract] [Full Text] [Related]
10. Community-acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities. Klugman KP, Low DE, Metlay J, Pechere JC, Weiss K. Int J Antimicrob Agents; 2004 Nov 15; 24(5):411-22. PubMed ID: 15519470 [Abstract] [Full Text] [Related]
11. Clarithromycin in 2003: sustained efficacy and safety in an era of rising antibiotic resistance. Anzueto A, Norris S. Int J Antimicrob Agents; 2004 Jul 15; 24(1):1-17. PubMed ID: 15225854 [Abstract] [Full Text] [Related]
12. Epidemiology, clinical characteristics and antimicrobial resistance patterns of community-acquired pneumonia in 1702 hospitalized children in Singapore. Chiang WC, Teoh OH, Chong CY, Goh A, Tang JP, Chay OM. Respirology; 2007 Mar 15; 12(2):254-61. PubMed ID: 17298459 [Abstract] [Full Text] [Related]
13. [Acute community-acquired pneumonia. A review of clinical trials]. Chidiac C. Med Mal Infect; 2006 Mar 15; 36(11-12):650-66. PubMed ID: 16876363 [Abstract] [Full Text] [Related]
14. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials. Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L. Clin Ther; 2006 Dec 15; 28(12):2061-9. PubMed ID: 17296462 [Abstract] [Full Text] [Related]
15. Barriers to the effective management of respiratory tract infections in the community. Saginur R. Infection; 2001 Dec 15; 29 Suppl 2():3-10. PubMed ID: 11785853 [Abstract] [Full Text] [Related]